Evaluate RYTM stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in RYTM? | Glauxie AI

Q: What are the risks of investing in RYTM?

Rhythm Pharmaceuticals, Inc. (RYTM) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO David Meeker. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The... Employees: 400,000.

Q: How much debt does RYTM have?

Review RYTM total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is RYTM a good long-term investment?

Evaluate RYTM as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in RYTM?

🦉

Rhythm Pharmaceuticals, Inc. (RYTM)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODavid Meeker

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of...

Key Executives

Name	Title
Alastair Garfield	Chief Scientific Officer
Christopher German	Corporate Controller & Principal Accounting Officer
David Connolly	Head of Investor Relations & Corporate Communications
David Meeker	Chairman, President & Chief Executive Officer
Elisabeth Cronert-Bendell	Senior Vice President & Head of Strategy
Hunter C. Smith	Chief Financial Officer & Treasurer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

RYTM Profile Financials

Is RYTM stock safe? How much debt does RYTM have? Is RYTM a good long-term investment?